From: Aromatherapy for the treatment of PONV in children: a pilot RCT
Control | Aromatherapy | |
---|---|---|
Age (YEAR) | 8.5 (95 % CI ±3.4) | 6.9 (95 % CI ±3.1) |
Sex (%male) | 9/18 (50 %) | 12/21 (57.1 %) |
ASA (I or II) | 100 % | 100 % |
Surgery | ||
ENT | 8/18 44 % | 17/21 81 % |
Ophthalmology | 5/18 27.8 % | 1/21 4.8 % |
Plastic surgery | 2/18 11.1 % | 0/21 0 % |
Orthopaedics | 0/18 0 % | 0/21 0 % |
Dental | 1/18 5.6 % | 3/21 14.3 % |
Urology | 0/18 0 % | 0/21 0 % |
General surgery | 2/18 11.1 % | 0/21 0 % |
OR time (minutes) | 66 (95 % CI ±18) | 64 (95 % CI ±34) |
PONV Prophylaxis | ||
TIVA | 4/18 22 % | 4/21 19 % |
Ondansetron | 14/18 77.8 % | 15/21 71 % |
Dexamethasone | 17/18 94.4 % | 18/21 85.7 % |
Pain management | ||
Acetaminophen | 17/18 94.4 % | 20/21 95.2 % |
Ketorolac | 6/18 33 % | 2/21 9.5 % |
Morphine dose (mg/kg) | 0.14 (95 % CI ±0.1) | 0.13 (95 % CI ±0.09) |